Design a decision-making aid: "alternative treatment for prostate cancer: what option do you prefer?"
Abstract
Purpose: To design a Decision-making Aid within the ‘Benign Prostatic Hyperplasia’ healthcare process modelling of the Andalusian Public Health System (SSPA) for the therapeutic approach of early-stage disease. Methods: The Decision Aid design was conducted in four phases: 1) Explore the receptiveness of professionals in the mainstream of the SSPA Decision Aid “Benign Prostatic Hyperplasia” process; 2) Select a Decision Aid from international experiences; 3) Transcultural adaptation of above selected Decision Aid; 4) Decision Aid Validation in the SSPA. Results: The results of the validation of Decision Aid “Alternative treatment for prostate cancer: What option do I prefer?” have shown that the document is well taken by patients, their design is attractive and the quality of clinical information it contains is high. The instrument meets the concerns of patients (95%), the language is simple and suitable (92%) and summarizes the essential information to make the decision (92%). The Decision Aid offers relevant information that help the patient in the decision making process (lack of decisional confl ict: 88.93), generates a sense of support (92.82), concerning the decision (86.88) and a sense of availability of information (90.51). Conclusion: Patients and professionals agree to recommend the use of Decision Aid. To improve information and enhance the tranquillity of the patient, the Decision Aid facilitates communication doctor patient consultation and the involvement of patients during the decision-making process.Downloads
Article download
License
In order to support the global exchange of knowledge, the journal Psicooncología is allowing unrestricted access to its content as from its publication in this electronic edition, and as such it is an open-access journal. The originals published in this journal are the property of the Complutense University of Madrid and any reproduction thereof in full or in part must cite the source. All content is distributed under a Creative Commons Attribution 4.0 use and distribution licence (CC BY 4.0). This circumstance must be expressly stated in these terms where necessary. You can view the summary and the complete legal text of the licence.